Article Details

Phase 3 mCRPC study of novel PSMA-targeted therapy hits key milestone

Retrieved on: 2021-08-11 20:37:30

Tags for this article:

Click the tags to see associated articles and topics

Phase 3 mCRPC study of novel PSMA-targeted therapy hits key milestone. View article details on hiswai:

Excerpt

We look forward to starting the randomization part of the trial phase globally,” Neil Fleshner, MD, chief medical officer of POINT Biopharma, the ...

Article found on: www.urologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up